Targeting Solid Tumors & Hematological Malignancies with ADCs Utilizing Auristatin, Topo1i & Dual Payloads
- Hydrophilic linker with optimized cleavable moiety enables efficient auristatin, exatecan / topoisomerase 1 and novel modality linker-payloads for ADC generation
- DAR4 and DAR8 MMAU auristatin ADCs showed outstanding therapeutic window against solid tumors and hematological malignancies
- Utilizing optimized linker and conjugation technologies for dual-payload ADCs